27 Dec 2012 | 01:14 pm | 1 min. read
International law firm Pinsent Masons has advised DCC Healthcare on the conditional agreement to acquire Kent Pharmaceutical (Holdings) Limited, a leading British generic pharmaceuticals company, for €71.2 million (Stg£58.0 million). Completion of the acquisition is conditional on approval from the Irish Competition Authority and it is anticipated that the transaction will complete in early 2013.
Kent Pharma is involved in the development, manufacture, sales, marketing and distribution of generic pharmaceuticals for the British, Irish and international markets. It principally sells into the retail pharmacy channel as well as into to hospitals, other generic pharma companies and international distributors. The business is headquartered in Ashford, Kent and has an Irish manufacturing site in Ireland.
DCC Healthcare, which has been active in the pharmaceutical market since 2002, is part of Dublin-based support services company DCC plc.
Tommy Breen, Chief Executive of DCC plc, said: "The acquisition of Kent Pharma is a material step forward for DCC Healthcare. For some time DCC has believed that there is an opportunity to build a substantial pharma business principally focused on established niche generic products that are a number of years post patent expiry. Such products are well positioned to benefit from the macro trend for healthcare systems to seek to meet the increasing demands of ageing populations with more cost effective healthcare solutions. In addition, the pharma market is fragmented offering value enhancing bolt on acquisition opportunities, in particular where a strong platform has been established.
Kent Pharma is an excellent strategic fit for DCC Healthcare's existing pharma business and their combined strengths will create new growth opportunities for DCC."
The Pinsent Masons team was led by Andrew Kerr, Partner and head of the Leeds' corporate team, assisted by Emma Shield and Lucie Miller (corporate) as well as a cross group team of specialist lawyers.
Key Contacts
Multinational law firm Pinsent Masons has advised Tokai Carbon Co., Ltd. (“Tokai Carbon”) on the sale of its German subsidiary TOKAI ERFTCARBON GmbH (“TEG”), to Lenbach Equity Opportunities III. GmbH & Co. KG, which is exclusively advised by DUBAG Investment Advisory GmbH (“DUBAG”).
Multinational law firm Pinsent Masons has advised the shareholders of independent financial advisory and wealth management firm Shackleton, including the private equity buy-and-build specialist Sovereign Capital Partners, on the exit to Lee Equity Partners.
Multinational law firm Pinsent Masons has been announced by Business in the Community as one of The Times Top 50 Employers for Gender Equality in 2025. This year’s list marks the sixth time that the firm has been recognised for its commitment to embedding gender equality into all levels of the organisation.
Multinational law firm Pinsent Masons has advised Tokai Carbon Co., Ltd. (“Tokai Carbon”) on the sale of its German subsidiary TOKAI ERFTCARBON GmbH (“TEG”), to Lenbach Equity Opportunities III. GmbH & Co. KG, which is exclusively advised by DUBAG Investment Advisory GmbH (“DUBAG”).
Multinational law firm Pinsent Masons has advised the shareholders of independent financial advisory and wealth management firm Shackleton, including the private equity buy-and-build specialist Sovereign Capital Partners, on the exit to Lee Equity Partners.
Multinational law firm Pinsent Masons has been announced by Business in the Community as one of The Times Top 50 Employers for Gender Equality in 2025. This year’s list marks the sixth time that the firm has been recognised for its commitment to embedding gender equality into all levels of the organisation.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]